GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 15, 2024 -- Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published online April 23 in Diabetes, Obesity, and Metabolism.
Osvaldo P. Almeida, Ph.D., from University of Notre Dame in Fremantle, Australia, and colleagues assessed whether dispensing of GLP-1 receptor agonists is associated with increased dispensing of antidepressants. The analysis included a 10 percent random sample of the Australian Pharmaceutical Benefits Scheme data (2012 to 2022).
The researchers found that 358,075 of 1.7 million individuals were dispensed antidepressants, and 8,495 of the 24,783 dispensed a GLP-1 receptor agonist were also dispensed an antidepressant in 2022 (odds ratio, 1.44). Among 24,103 individuals dispensed a GLP-1 receptor agonist between 2012 and 2021, 8,083 were dispensed antidepressants in 2022 (odds ratio, 1.52). Among 1.2 million individuals who had not been dispensed antidepressants in 2012, there was a heightened risk for being dispensed an antidepressant between 2013 and 2022 following the dispensing of a GLP-1 receptor agonist (hazard ratio, 1.19).
"Individuals exposed to GLP-1 receptor agonists are at greater risk of being dispensed antidepressants," the authors write. "The possible impact of GLP-1 receptor agonists on the mood of consumers requires ongoing vigilance and further research."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Recent Years Saw Increase in Youth With Anxiety, Depression
MONDAY, April 28, 2025 -- From 2016 to 2022, there was an increase in the proportion of youth who experienced anxiety or depression, according to a research letter published...
USPSTF Recommends Counseling to Prevent Perinatal Depression
FRIDAY, April 25, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends counseling for women at increased risk for perinatal depression (PND). This recommendation...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.